Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Erasmus University Medical Center
- Harvard Medical School
- Aarhus Universitet
- The Health Improvement Network
- Health Search Database
- King's College London
- South London and Maudsley NHS Foundation Trust
- University of Glasgow
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceuticals Inc.
Purpose: Real-world studies to describe the use of first, second and third line therapies for the management and symptomatic treatment of dementia are lacking. This retrospective cohort study describes the first-, second- and third-line therapies used for the management and symptomatic treatment of dementia, and in particular Alzheimer’s Disease. Methods: Medical records of patients with newly diagnosed dementia between 1997 and 2017 were collected using four databases from the UK, Denmark, Italy and the Netherlands. Results: We identified 191,933 newly diagnosed dementia patients in the four databases between 1997 and 2017 with 39,836 (IPCI (NL): 3281, HSD (IT): 1601, AUH (DK): 4474, THIN (UK): 30,480) fulfilling the inclusion criteria, and of these, 21,131 had received a specific diagnosis of Alzheimer’s disease. The most common first line therapy initiated within a year (± 365 days) of diagnosis were Acetylcholinesterase inhibitors, namely rivastigmine in IPCI, donepezil in HSD and the THIN and the N-methyl-d-aspartate blocker memantine in AUH. Conclusion: We provide a real-world insight into the heterogeneous management and treatment pathways of newly diagnosed dementia patients and a subset of Alzheimer’s Disease patients from across Europe.
|Journal||Social Psychiatry and Psychiatric Epidemiology|
|Publication status||Accepted/In press - 2020|